ArticleJournal of translational medicine2023

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.

Caterina Riillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.